Alnylam reports preliminary FY2024 net product revenues of $1.65B (+33% YoY); guides FY2025 $2.05-2.25B

ALNYLAM PHARMACEUTICALS, INC.

2024-FY EPS reported -$2.18 revenue$2,248,243,000

Q4 2024 net product revenues ~$451M; FY2024 ~$1,646M, representing 33% annual growth.
2025 combined net product revenue guidance of $2.05B-$2.25B, 31% growth at mid-point vs 2024.
TTR franchise (ONPATTRO/AMVUTTRA): FY2024 ~$1,223M; 2025 guidance $1.6B-$1.725B (36% growth).
Rare franchise (GIVLAARI/OXLUMO): FY2024 ~$423M; 2025 guidance $450M-$525M (15% growth).
Company expects 2025 non-GAAP operating income profitability; vutrisiran PDUFA date March 23, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.